Finder's Pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Immunomedics is a biotechnology business based in the US. Immunomedics stocks (IMMU.US) are listed on the NASDAQ and all prices are listed in US Dollars. Immunomedics employs 366 staff and has a trailing 12-month revenue of around $20.4 million.
|52-week range||$0.00 - $0.00|
|50-day moving average||$86.42|
|200-day moving average||$49.32|
|Wall St. target price||$75.77|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.63|
Note: The dollar amounts in the table below are in Canadian dollars.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
|Revenue TTM||$20.4 million|
|Gross profit TTM||$-254,576,000|
|Return on assets TTM||-25.16%|
|Return on equity TTM||0%|
|Market capitalisation||$20.3 billion|
TTM: trailing 12 months
We're not expecting Immunomedics to pay a dividend over the next 12 months.
Immunomedics's shares were split on a 2:1 basis on 24 June 1985. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Immunomedics shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Immunomedics shares which in turn could have impacted Immunomedics's share price.
Over the last 12 months, Immunomedics's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Immunomedics's is 2.9018. This would suggest that Immunomedics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Immunomedics, Inc. , a clinical-stage biopharmaceutical company, develops monoclonal antibody-based products for the targeted treatment of cancer. It develops sacituzumab govitecan, an antibody-drug conjugate for the treatment of patients with metastatic triple-negative breast cancer. The company focuses on commercializing sacituzumab govitecan as a third-line therapy for patients with metastatic triple-negative breast cancer in the United States. The company also develops IMMU-140 for treatment of hematologic malignancies; and IMMU-130 to treat Colorectal cancer. Its other product candidates includes epratuzumab, an anti-CD22 antibody; veltuzumab, an anti-CD20 antibody; milatuzumab, an anti-CD74 antibody; and IMMU-114, a HLA-DR antibody. Immunomedics, Inc.
Everything we know about the Nauticus Robotics, Inc. IPO, plus information on how to buy in.
What is Mogo and how can you access its new trading platform, MogoTrade? Find out in our review.
Lido’s liquid staking allows investors holding LUNA and less than 32 ETH to reap the rewards of DeFi staking.
This guide provides step-by-step instructions on how to buy Bitcoin Private, lists some exchanges where you can get it and provides daily price data on BTCP.
Steps to owning and managing HAE stock, with 24-hour and historical pricing before you buy.
Steps to owning and managing Aritzia (ATZ) stock, with 24-hour and historical pricing before you buy.
Get low fees and access many different types of accounts, platforms and investments with this reputable online broker.
Read our expert analysis on Hifi Finance and how the token will perform in the future.
Read our expert analysis on Kusama and how the token will perform in the future.
This guide provides step-by-step instructions on how to buy Baby Doge Coin, lists some exchanges where you can get it and provides daily price data on BABYDOGE.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.